Just months after layoffs and pushing eye therapy, ProQR offloads eye portfolio in pivot to RNA-editing

The Dutch biotech announced early Thursday that it will be looking for a partner to take the company’s ophthalmology portfolio further into clinical trials. The company had said in a statement that after a pivotal trial failure back in February for lead candidate sepofarsen, the EMA had said that the biotech would need to conduct an additional pivotal clinical trial before filing for approval. And that trial won’t be done by ProQR.